ARVN

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

Retrieved on: 
fredag, maj 24, 2024
News, HER2, Investment, Pfizer, Chimera, Hallucination, Pancreas, Blood, Pancreatic cancer, Breast cancer, Anxiety, Medicine, Proteolysis, Therapy, TSX, Nucleic acid thermodynamics, Survival, TIL, PALM, ONC, TILS, Magnetic resonance imaging, ABBV, NASAR, MD, Gemcitabine, PFE, Immunotherapy, PDAC, ARVN, DSM-IV codes, Safety, FOLFIRINOX, Psychiatry, Research, Cancer, Rhinitis, ASCO, Society, Patient, Doctor of Philosophy, DNA, Prevalence, Diagnosis, Growth, Social media, Pancreatic Cancer Action Network, Abstract, Personalized medicine, ESMO, Oncolytics Biotech, Classic, Oncology, Annual general meeting, Pharmaceutical industry

With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts.

Key Points: 
  • With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts.
  • The report said: “This growth is driven by increasing instances of pancreatic cancer and higher investments in pancreatic oncology research.
  • In recent years, the pancreatic cancer market has experienced steady growth, largely driven by the increasing prevalence of pancreatic cancer cases globally.
  • BioSpace concluded: “Several notable trends are shaping the pancreatic cancer market.

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Retrieved on: 
torsdag, maj 23, 2024
Team Impulse, ARVN, CDK4, HER2, Chimera, Congress, Prostate cancer, CDK, Abstract, Society, Proteolysis, PROTAC, Birth control

NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer’s atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at the 2024 American Society of Clinical Oncology Annual Congress held May 31 to June 4, 2024, in Chicago, IL.

Key Points: 
  • NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer’s atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at the 2024 American Society of Clinical Oncology Annual Congress held May 31 to June 4, 2024, in Chicago, IL.
  • Presentation details are as follows:
    Title: ARV-766, a PROteolysis TArgeting Chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): initial results of a phase 1/2 study
    Presentation Type and Abstract Number: Rapid Oral Abstract, 5011
    Title: TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
    Presentation Type and Abstract Number: Trial-in-Progress (TiP) TPS1131, Poster 103b

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

Retrieved on: 
torsdag, maj 16, 2024
Patient, Progression-free survival, Fulvestrant, DNA, PROTAC, Febrile neutropenia, ARVN, HER2, Neutropenia, Fourth grade, PFS, Chimera, Safety, Cyclin-dependent kinase 4, Breast cancer, Congress, PFE, ESR1, Breast Cancer Research, Sarah Cannon Research Institute, Proteolysis, ESMO, CBR, Mutation, Pharmaceutical industry

NEW HAVEN, Conn. and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced updated clinical data from a Phase 1b combination cohort evaluating vepdegestrant, an investigational oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader, in combination with palbociclib (IBRANCE®). After six months of additional follow-up, these data are consistent with data presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2023, and show that vepdegestrant plus palbociclib continue to demonstrate encouraging clinical activity in heavily pre-treated patients with a median of four lines of prior therapy with locally advanced or metastatic ER positive (ER+)/human epidermal growth factor 2 (HER2) negative (ER+/HER2-) breast cancer. These updated data were presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress.

Key Points: 
  • These updated data were presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress.
  • “We're encouraged by the clinical activity and safety profile observed with vepdegestrant in combination with palbociclib in patients being treated for advanced ER+/HER2- breast cancer,” said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas.
  • Vepdegestrant is being co-developed by Arvinas and Pfizer and is being evaluated as a monotherapy in the second-line setting in the ongoing Phase 3 VERITAC-2 trial and in the first-line setting in combination with palbociclib in the ongoing study lead-in cohort of the Phase 3 VERITAC-3 trial.
  • The safety profile of vepdegestrant in combination with palbociclib was otherwise consistent with the profile of palbociclib and what has been observed in other clinical trials for vepdegestrant.

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

Retrieved on: 
torsdag, maj 9, 2024
Congress, CDK, Proteolysis, HER2, Breast cancer, Oncology, ARVN, ESMO, Chimera, Patient, Team Impulse, Poster, Clinical trial, PROTAC

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany.

Key Points: 
  • NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany.
  • Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
  • Poster session details are as follows:
    Time: 12:00 – 1:00 p.m. CET/ 6:00 – 7:00 a.m.
  • ET
    Poster Title and Number: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: updated phase 1b cohort results, Poster 218P
    Presentation Type and Abstract Number: Abstract, 453
    Poster Title and Number: TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer, Poster 264
    Presentation Type and Abstract Number: Trial-in-Progress (TiP), 488

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
tisdag, maj 7, 2024
Corporation, Sale, Greyhawk, License, Ribociclib, Palsy, HER2, General counsel, NVS, Food, ARVN, Research, Quantum Leap, Business development, Genentech, Development, Administration, Arm, Prostate cancer, Exercise, CDK7, Senior, Patient, Bayer, EOP, CDK4, Interim, PROTAC, LRRK2, Pharmaceutical industry

NEW HAVEN, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points: 
  • Announced the resignation of Chief Financial Officer and Treasurer, Sean Cassidy, effective February 29, 2024.
  • Research and Development Expenses: Research and development expenses were $84.3 million for the quarter ended March 31, 2024, as compared with $95.3 million for the quarter ended March 31, 2023.
  • General and Administrative Expenses: General and administrative expenses were $24.3 million for the quarter ended March 31, 2024, as compared with $24.9 million for the quarter ended March 31, 2023.
  • Revenues: Revenues were $25.3 million for the quarter ended March 31, 2024 as compared with $32.5 million for the quarter ended March 31, 2023.

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

Retrieved on: 
onsdag, april 24, 2024
ARVN, Executive, Patient, Growth, Management

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer.

Key Points: 
  • NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer.
  • Dr. Teel currently serves as Arvinas’ interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Officer, John Houston, Ph.D. Dr. Teel will remain in these interim roles at Arvinas while the board of directors continues its search for a permanent Chief Financial Officer and Treasurer.
  • "We are delighted to announce Randy's promotion to Chief Business Officer,” said John Houston, Ph.D., Chairperson, President and Chief Executive Officer at Arvinas.
  • At Arvinas, in addition to finance, he also leads corporate strategy, business development, investor relations, and communications.

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Retrieved on: 
torsdag, april 11, 2024
Sale, License, NVS, ARVN, Goldman Sachs, Research, Prostate cancer, Patient, PROTAC, Pharmaceutical industry

NEW HAVEN, Conn., April 11, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS) for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.

Key Points: 
  • The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.
  • “We believe the expertise and scale of Novartis will broaden the development of ARV-766 and its potential to be a first- and best-in-class treatment for patients with prostate cancer.
  • Under the License Agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 billion, as well as tiered royalties for ARV-766.
  • Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Arvinas.

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
måndag, mars 18, 2024
Employment, Development, ARVN, PROTAC, Pfizer, Oncology, Partnership, Novartis, Executive, Patient, Knowledge, National Cancer Institute, Bristol Myers Squibb, BMS, Neuroscience, Columbia University, LRRK2, Pharmaceutical industry

Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.

Key Points: 
  • Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.
  • “We are thrilled to have Dr. Berkowitz join Arvinas as we continue advancing multiple programs with the goal of improving the lives of patients with serious diseases,” said John Houston, Ph.D., Chairperson, President and Chief Executive Officer at Arvinas.
  • Dr. Berkowitz joins Arvinas from Bristol-Myers Squibb (BMS), where he was Senior Vice President, Development Unit Head, Hematology.
  • The option and restricted stock units were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

Arvinas to Participate in Upcoming Investor Conferences

Retrieved on: 
måndag, mars 4, 2024
ARVN, Neuroscience, Conference, Life insurance

NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:

Key Points: 
  • NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
    Leerink Partners Global Biopharma Conference on Tuesday, March 12.
  • Ron Peck, M.D., chief medical officer, and Randy Teel, Ph.D., interim chief financial officer, will participate in a fireside chat.
  • Ron Peck, M.D., chief medical officer, and Randy Teel, Ph.D., interim chief financial officer, will participate in investor 1x1 meetings.
  • Ian Taylor, Ph.D., chief scientific officer, and Angela Cacace, Ph.D., senior vice president of neuroscience and platform biology, will participate in a fireside chat.

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
tisdag, februari 27, 2024
CDK4, ESPP, Research, BCL6, Sale, Exercise, LRRK2, ARVN, CDK7, ATM, HER2, Genentech, European Medicines Agency, Congress, Development, Breast cancer, Pfizer, CBR, ESMO, Everolimus, Greyhawk, ESR1, Oncology, Enrollment, Investment, Insurance, Prostate cancer, PFS, Food, Ribociclib, Bayer, Administration, Patient, Neutropenia, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Median PFS of 11.1 and 11.0 months in patients with ESR1 wild-type and ESR1 mutant tumors, respectively.
  • Announced the appointment of Randy Teel, Ph.D., Arvinas’ current senior vice president of corporate and business development, to the role of interim chief financial officer and treasurer.
  • The Arvinas Board of Directors has launched a formal search process to identify Mr. Cassidy’s permanent replacement.
  • Revenues: Revenue was $78.5 million and $(43.1) million for the year and quarter ended December 31, 2023 as compared with $131.4 million and $38.0 million for the year and quarter ended December 31, 2022.